Abbott India Share Price Today (ABBOTINDIA)
TODAY IN ONE LINE
Closed at ₹27,385 (−0.04%); delivery 48.0%. Market opens 9:15 IST. · as of 11:19 IST
With a market cap of ₹58,138.09 Cr., it trades at a P/E of 37.53. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Abbott India flags
Key strengths and potential risks.
Green Flags
- ●High Capital EfficiencyROCE of 44.9% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 34.5%
- ●Healthy Operating MarginsOPM is structurally strong at 27.3%
- ●High Promoter HoldingPromoters hold 75.0% skin-in-the-game
- ●Steady Dividend YieldReliable 1.77% dividend yield
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Rising Receivables vs SalesReceivables grew 52.4% outpacing sales growth of 9.6%
What changed recently?
Recent events, corporate actions, and announcements.
Abbott India Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Abbott India Limited, framed against the sector median so the premium or discount is obvious at a glance.
Abbott India Limited trades at a P/E of 37.53× and P/B of 12.20×, against the Healthcare sector median P/E of 39.23×.
Valuation
Profitability
Growth
Financial Health
Abbott India Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Abbott India Limited — derived from the live tape, not yesterday's close.
Abbott India Limited last traded at ₹27,385 with an intraday range of ₹27,305–₹27,570 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹27385.00| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 28065.00 | +680.00 | +2.48% |
| R3 | 27800.00 | +415.00 | +1.52% |
| R2 | 27685.00 | +300.00 | +1.10% |
| R1 | 27535.00 | +150.00 | +0.55% |
| PIVOT | 27420.00 | 35.00 | 0.13% |
| CURRENT | 27385.00 | — | — |
| S1 | 27270.00 | -115.00 | -0.42% |
| S2 | 27155.00 | -230.00 | -0.84% |
| S3 | 27005.00 | -380.00 | -1.39% |
| S4 | 26740.00 | -645.00 | -2.36% |
ABBOTINDIA is trading Below CPR, indicating Bearishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ₹27305–₹27570
Trading Inside opening range
Abbott India Limited financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Abbott India Limited, switchable between annual and quarterly views, consolidated or standalone.
Abbott India Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹58,138.09 Cr. and reported EPS of ₹729.61.
Abbott India segment analysis: revenue and profit mix.
Disclosed business segments at Abbott India with their share of revenue and profit, switchable between consolidated and standalone reporting.
Abbott India discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Abbott India Limited.
Our AI distills the core fundamental drivers supporting Abbott India Limited, the risks that threaten it, and the exact valuation or growth triggers that should make you re-evaluate.
Abbott India Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
ROE 34.50% and ROCE 44.90% substantially exceed pharmaceutical sector benchmarks of ~15%.
Operating margin 26.21% significantly surpasses pharma sector average of ~20%, demonstrating pricing power.
Debt-to-equity 0.0004x with minimal total debt ₹172 Cr ensures fortress-like balance sheet stability.
Promoter holding 74.99% signals strong founder commitment and long-term strategic alignment with shareholders.
Latest quarterly EPS grew 7.60% YoY despite intense competitive pharmaceutical industry pressures.
Key Risks.
P/E ratio 35.64x trades substantially above peer median 28.20x, limiting near-term valuation appeal.
P/B ratio 11.92x indicates significant premium to tangible book value, reflecting stretched valuation.
FII holdings minimal at 0.16%, reflecting weak foreign investor conviction in the stock.
Dividend payout ratio 65.10% constrains retained earnings available for aggressive reinvestment.
52-week price return flat at 0%, indicating stagnant momentum despite strong underlying fundamentals.
Flip Conditions.
Trim if P/E re-rates above 49 (~1.2× the sector multiple of 39.2). The valuation cushion thins from there.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Exit if ROE slips below 30%. The operating engine is no longer compounding capital efficiently.
Income thesis breaks if the dividend is cut or yield falls below 0.89%.
Abbott India Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Abbott India Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Abbott India Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Abbott India Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Abbott India Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Abbott India Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Abbott India Limited stood at 48.0% of traded volume, against a 20-day average of 60.5%.
Abbott India announcements: results, concalls, ratings, M&A.
Filings Abbott India sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Abbott India files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 61 documents below.
Company Update
Communication to Shareholders - Intimation about Tax Deduction at Source on Dividend.
Company Update
Newspaper Advertisement - Special Window for Transfer and Dematerialization of Physical Securities.
Company Update
Newspaper Advertisement - Reminder to Shareholders - Unclaimed Dividends.
Investor decks & rating reports.
Abbott India dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Abbott India has declared, sequenced by announce and record date.
Abbott India corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Abbott India Limited: business, sector, key facts.
What Abbott India Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Abbott India Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: ABBOTINDIA, BSE: 500488.
Abbott India Limited is a prominent pharmaceutical company operating within India. Its business model centers on the research, development, manufacturing, and distribution of a wide range of pharmaceutical products catering to diverse therapeutic areas. The company's portfolio is extensive and addresses significant unmet medical needs across the Indian population.
A key aspect of Abbott India's business is its focus on specific therapeutic areas. These include gastroenterology, women's health, metabolic disorders, central nervous system conditions, and vaccines. The company also offers products for multispecialty needs, encompassing conditions such as insomnia, vitamin D deficiency, preterm labor, and pain management. This diversified approach allows Abbott India to serve a broad spectrum of patients and healthcare providers.
Further diversification is evident in Abbott India's product categories. The company manufactures and markets anti-infective agents, cardio-diabetological medications, hepatology products, hormone therapies, neuro-psychiatric medications, hepatic treatments, and products categorized as 'gennext' (likely referring to newer generation pharmaceuticals). A consumer care segment also forms part of their offerings, indicating a broader reach beyond purely prescription-based pharmaceuticals.
Abbott India's long history, dating back to 1910, speaks to its established presence and experience within the Indian pharmaceutical market. Headquartered in Mumbai, the company operates as a subsidiary of Abbott Capital India Limited, benefiting from the resources and expertise of its parent company. This structural positioning likely supports Abbott India's continued growth and market competitiveness.
In summary, Abbott India's business is characterized by its diversified pharmaceutical portfolio addressing major therapeutic areas and diverse patient needs. The company's long operational history, strategic focus, and parent company support contribute to its significant position within the Indian pharmaceutical landscape. Its range extends from prescription-based treatments to consumer healthcare products, allowing it to cater to a wide audience.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B Blackbio DX (3BBLACKBIO) Share PricePeer
- Acutaas Chemicals (ACUTAAS) Share PricePeer
- Anlon Healthcare (AHCL) Share PricePeer
- Amanta Healthcare (AMANTA) Share PricePeer
- Ambalal Sarabhai Enterprises (AMBALALSA) Share PricePeer
- Top quality scorecard stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Abbott India Limited (ABBOTINDIA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Abbott India Limited (ABBOTINDIA)?
The current share price of Abbott India Limited (ABBOTINDIA) is ₹27,385. Today, the stock has declined by ₹10.00 (0.04%), trading in a range of ₹27,305 to ₹27,570. The stock opened at ₹27,415 with a trading volume of 5,382 shares.
02Is Abbott India Limited stock a good investment for long-term?
Abbott India Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹58,138.09 crores, P/E ratio of 37.53, ROE of 34.50%, and ROCE of 44.90%. The dividend yield stands at 1.77%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Abbott India Limited stock?
The 52-week high price of Abbott India Limited (ABBOTINDIA) is ₹35,310, while the 52-week low is ₹25,150. Currently trading at ₹27,385, the stock is 22.0% away from its 52-week low and 22.4% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Abbott India Limited stock at the current price?
Whether to buy Abbott India Limited stock at ₹27,385 depends on multiple factors. The stock is currently trading with a P/E ratio of 37.53 and P/B ratio of 12.20. Today's performance shows a loss of 0.04%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Abbott India Limited and when is the next dividend?
Abbott India Limited offers a dividend yield of 1.77%, which means for every ₹100 invested at the current price of ₹27,385, you can expect to receive approximately ₹1.77 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Abbott India Limited?
Abbott India Limited's key financial metrics include: P/E Ratio: 37.53, P/B Ratio: 12.20, ROE: 34.50%, ROCE: 44.90%, Dividend Yield: 1.77%, EPS: ₹729.61, Book Value: ₹2,246.69, and Debt-to-Equity: 0.00. The company's market cap stands at ₹58,138.09 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Abbott India Limited stock performing today in the market?
Abbott India Limited stock opened at ₹27,415 and is currently trading at ₹27,385, showing a decline of ₹10.00 (0.04%). The intraday high is ₹27,570 and low is ₹27,305. The trading volume stands at 5,382 shares, indicating moderate market participation today.
08What is the P/E ratio of Abbott India Limited and what does it indicate?
Abbott India Limited has a Price-to-Earnings (P/E) ratio of 37.53, which means investors are willing to pay ₹37.53 for every ₹1 of earnings. With an EPS of ₹729.61, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Abbott India Limited (ABBOTINDIA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.